Hamilton Lane Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Hamilton Lane Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-18,519	Closed	-$2.39M	–	78
2021 Q1	$2.39M	Buy	+18,519	New	+$2.81M	0.78%	29

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Hamilton Lane Advisors's ASND Position: Q2 2021 in Review

Hamilton Lane Advisors sold out of Ascendis Pharma A/S (ASND) in Q2 2021, closing a stake of 18,519 shares — an estimated $2.39M sold.

Hamilton Lane Advisors first reported a position in ASND in Q1 2021 and held it in 1 quarter. The position peaked at $2.39M in Q1 2021. 171 funds tracked by Wall St. Rank hold ASND as of Q2 2021.

Hamilton Lane Advisors reported no remaining Ascendis Pharma A/S position as of Q2 2021 after selling out during the quarter.
Hamilton Lane Advisors sold 18,519 Ascendis Pharma A/S shares in Q2 2021, an estimated $2.39M.
Hamilton Lane Advisors first reported a position in Ascendis Pharma A/S in Q1 2021 and held it in 1 quarter.
Hamilton Lane Advisors's Ascendis Pharma A/S position peaked at $2.39M in Q1 2021.
171 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2021.

Based on Hamilton Lane Advisors's 13F filing for Q2 2021, filed 20 Jul 2021.